LAVA Therapeutics stock rises on acquisition deal with XOMA Royalty

XOMA Royalty Corporation has agreed to acquire LAVA Therapeutics N.V. for $1.16-$1.24 per share in cash, augmented by a contingent value right (CVR) representing 75% of net proceeds from LAVA’s partnered and unpartnered assets. LAVA’s Board unanimously approved the deal following a strategic review aimed at maximizing shareholder value, with XOMA emphasizing the potential of LAVA’s gamma delta bispecific antibody programs. The transaction, which will lead to the discontinuation of LAVA's LAVA-1266 Phase 1 clinical trial, is anticipated to close in Q4 2025, pending an 80% share tender and shareholder approval.

Analysis

XOMA Royalty Corporation has entered into a definitive agreement to acquire LAVA Therapeutics N.V. in a deal structured with both upfront cash and potential long-term upside. The terms include a cash payment of $1.16 to $1.24 per share and a non-transferable contingent value right (CVR) representing 75% of future net proceeds from LAVA's partnered and unpartnered programs. This transaction is the result of a strategic review by LAVA's board, which unanimously approved the offer, suggesting this was viewed as the optimal outcome for maximizing shareholder value. From XOMA's perspective, the acquisition provides strategic access to LAVA's gamma delta bispecific antibody programs, which its management views as highly promising. A direct operational consequence of the deal is the discontinuation of LAVA's Phase 1 clinical trial of LAVA-1266. Following the announcement, LAVA's stock rose 4.2%, indicating a positive market reception. The deal's closure is projected for the fourth quarter of 2025, contingent on meeting several conditions, most notably the tender of at least 80% of LAVA's outstanding shares.

Key Decisions for Investors

• LAVA Therapeutics shareholders must assess the total value of the offer by combining the guaranteed cash component with the uncertain but potentially significant long-term value of the 75% CVR on program proceeds.
• Investors in XOMA Royalty should consider this a strategic bolt-on acquisition and monitor the clinical and commercial progress of LAVA's partnered antibody programs, which will ultimately determine the transaction's return on investment.
• Given the extended timeline to a Q4 2025 close and the high 80% tender condition, investors should factor in significant execution risk and a prolonged period of uncertainty before the transaction is finalized.